tailieunhanh - Báo cáo y học: "A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. | Shiina et al. Annals of General Psychiatry 2010 9 27 http content 9 1 27 ANNALS OF GENERAL PSYCHIATRY PRIMARY RESEARCH Open Access Arandomised double-blind placebo-controlled trial of tropisetron in patients with schizophrenia Akihiro Shiina1 Yukihiko Shirayama2 Tomihisa Niitsu3 Tasuku Hashimoto3 Taisuke Yoshida3 Tadashi Hasegawa1 Tadashi Haraguchi3 Nobuhisa Kanahara3 Tetsuya Shiraishi3 Mihisa Fujisaki1 Goro Fukami1 Michiko Nakazato1 Masaomi lyo1 3 and Kenji Hashimoto 4 Abstract Background Cognitive deficits in schizophrenia are associated with psychosocial deficits that are primarily responsible for the poor long-term outcome of this disease. Auditory sensory gating P50 deficits are correlated with neuropsychological deficits in attention one of the principal cognitive disturbances in schizophrenia. Our studies suggest that the a7 nicotinic acetylcholine receptor a7 nAChR agonist tropisetron might be a potential therapeutic drug for cognitive deficits in schizophrenia. Therefore it is of particular interest to investigate the effects of tropisetron on the cognitive deficits in patients with schizophrenia. Methods A randomised placebo-controlled trial of tropisetron in patients with schizophrenia was performed. A total of 40 patients with chronic schizophrenia who had taken risperidone 2 to 6 mg day were enrolled. Subjects were randomly assigned to a fixed titration of tropisetron n 20 10 mg day or placebo n 20 in an 8-week double-blind trial. Auditory sensory gating P50 deficits and Quality of Life Scale QLS Cambridge Neuropsychological Test Automated Battery CANTAB and Positive and Negative Syndrome Scale PANSS scores were measured. Results In all 33 patients completed the trial. Tropisetron was well tolerated. Administration of tropisetron but not placebo significantly improved auditory sensory gating P50 deficits in non-smoking patients with schizophrenia. The score on the rapid visual information processing sustained visual .

TÀI LIỆU LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.